• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques.抗体介导增强猿猴免疫缺陷病毒(SIV)感染的恒河猴体内SIV Gag抗原加工及交叉呈递的证据。
J Virol. 2003 Jan;77(1):10-24. doi: 10.1128/jvi.77.1.10-24.2003.
2
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.基于金丝雀痘病毒载体-猴免疫缺陷病毒gag-pol-env的疫苗接种以及猕猴主要组织相容性复合体I类(A*01)延缓猴免疫缺陷病毒SIVmac诱导的免疫缺陷。
J Virol. 2002 Jan;76(1):292-302. doi: 10.1128/jvi.76.1.292-302.2002.
3
Escape in one of two cytotoxic T-lymphocyte epitopes bound by a high-frequency major histocompatibility complex class I molecule, Mamu-A*02: a paradigm for virus evolution and persistence?在由高频主要组织相容性复合体I类分子Mamu - A*02结合的两种细胞毒性T淋巴细胞表位之一中逃逸:病毒进化与持续存在的范例?
J Virol. 2002 Nov;76(22):11623-36. doi: 10.1128/jvi.76.22.11623-11636.2002.
4
Novel simian immunodeficiency virus CTL epitopes restricted by MHC class I molecule Mamu-B*01 are highly conserved for long term in DNA/MVA-vaccinated, SHIV-challenged rhesus macaques.受MHC I类分子Mamu - B*01限制的新型猿猴免疫缺陷病毒CTL表位在经DNA/MVA疫苗接种并受到SHIV攻击的恒河猴中长期高度保守。
Int Immunol. 2005 May;17(5):637-48. doi: 10.1093/intimm/dxh245. Epub 2005 Apr 11.
5
CD8(+) lymphocytes from simian immunodeficiency virus-infected rhesus macaques recognize 14 different epitopes bound by the major histocompatibility complex class I molecule mamu-A*01: implications for vaccine design and testing.来自感染猿猴免疫缺陷病毒的恒河猴的CD8(+)淋巴细胞识别由主要组织相容性复合体I类分子Mamu-A*01结合的14种不同表位:对疫苗设计和测试的意义。
J Virol. 2001 Jan;75(2):738-49. doi: 10.1128/JVI.75.2.738-749.2001.
6
Identification of seventeen new simian immunodeficiency virus-derived CD8+ T cell epitopes restricted by the high frequency molecule, Mamu-A*02, and potential escape from CTL recognition.鉴定出17个由高频分子Mamu - A*02限制的新的猿猴免疫缺陷病毒衍生的CD8 + T细胞表位以及潜在的CTL识别逃逸情况。
J Immunol. 2004 Oct 15;173(8):5064-76. doi: 10.4049/jimmunol.173.8.5064.
7
Linking pig-tailed macaque major histocompatibility complex class I haplotypes and cytotoxic T lymphocyte escape mutations in simian immunodeficiency virus infection.将猪尾猕猴主要组织相容性复合体I类单倍型与猿猴免疫缺陷病毒感染中的细胞毒性T淋巴细胞逃逸突变联系起来。
J Virol. 2014 Dec;88(24):14310-25. doi: 10.1128/JVI.02428-14. Epub 2014 Oct 1.
8
Use of major histocompatibility complex class I/peptide/beta2M tetramers to quantitate CD8(+) cytotoxic T lymphocytes specific for dominant and nondominant viral epitopes in simian-human immunodeficiency virus-infected rhesus monkeys.利用主要组织相容性复合体I类/肽/β2微球蛋白四聚体来定量恒河猴感染猿猴-人类免疫缺陷病毒后针对显性和非显性病毒表位的CD8(+) 细胞毒性T淋巴细胞。
J Virol. 1999 Jul;73(7):5466-72. doi: 10.1128/JVI.73.7.5466-5472.1999.
9
A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge.疫苗引发的、单一病毒表位特异性细胞毒性T淋巴细胞反应不能抵御静脉内无细胞猿猴免疫缺陷病毒攻击。
J Virol. 1995 Apr;69(4):2279-84. doi: 10.1128/JVI.69.4.2279-2284.1995.
10
Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus.恒河猴主要组织相容性复合体I类分子(Mamu - A*01)的肽结合基序的特征分析,该分子可结合来自猿猴免疫缺陷病毒的免疫显性细胞毒性T淋巴细胞表位。
J Immunol. 1998 Jun 15;160(12):6062-71.

引用本文的文献

1
Analytical treatment interruption among women with HIV in southern Africa who received VRC01 or placebo in the Antibody Mediated Prevention Study: ATI stakeholder engagement, implementation and early clinical data.在南部非洲接受抗体介导预防研究中VRC01或安慰剂的感染艾滋病毒女性中分析性治疗中断:ATI利益相关者参与、实施及早期临床数据
J Int AIDS Soc. 2025 Jun;28(6):e26495. doi: 10.1002/jia2.26495.
2
Self-Tumor Antigens in Solid Tumors Turned into Vaccines by α-gal Micelle Immunotherapy.通过α-半乳糖胶束免疫疗法将实体瘤中的自身肿瘤抗原转化为疫苗。
Pharmaceutics. 2024 Sep 27;16(10):1263. doi: 10.3390/pharmaceutics16101263.
3
Coordinated antiviral immune response in a patient with myeloma and systemic adenovirus infection post-BCMA CAR T cells.一名多发性骨髓瘤患者在接受靶向B细胞成熟抗原(BCMA)的嵌合抗原受体(CAR)T细胞治疗后发生系统性腺病毒感染时的协调抗病毒免疫反应
Blood Adv. 2024 Nov 26;8(22):5880-5884. doi: 10.1182/bloodadvances.2024012762.
4
Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA.抗体 Fc 嵌合体和效应功能:当 IgG 利用 IgA 时。
Front Immunol. 2023 Feb 2;14:1037033. doi: 10.3389/fimmu.2023.1037033. eCollection 2023.
5
Fc-Dependent Immunomodulation Induced by Antiviral Therapeutic Antibodies: New Perspectives for Eliciting Protective Immune Responses.抗病毒治疗性抗体诱导的Fc依赖性免疫调节:引发保护性免疫反应的新视角
Antibodies (Basel). 2022 Jul 26;11(3):50. doi: 10.3390/antib11030050.
6
HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies.HIV-1 储存库的持久性和衰减:对治愈策略的影响。
Curr HIV/AIDS Rep. 2022 Jun;19(3):194-206. doi: 10.1007/s11904-022-00604-2. Epub 2022 Apr 11.
7
Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune-Complexing with the Natural Anti-Gal Antibody.通过与天然抗半乳糖抗体进行原位免疫复合提高包膜全病毒疫苗的效力
Med Res Arch. 2021 Jul;9(7). doi: 10.18103/mra.v9i7.2481. Epub 2021 Jul 10.
8
Amplifying immunogenicity of prospective Covid-19 vaccines by glycoengineering the coronavirus glycan-shield to present α-gal epitopes.通过糖基工程改造冠状病毒聚糖护盾以呈现 α-半乳糖表位,增强潜在的 Covid-19 疫苗的免疫原性。
Vaccine. 2020 Sep 29;38(42):6487-6499. doi: 10.1016/j.vaccine.2020.08.032. Epub 2020 Aug 19.
9
Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection.早期接触广泛中和抗体可能会引发从进行性疾病到持久控制 SHIV 感染的动态转变。
PLoS Comput Biol. 2020 Aug 20;16(8):e1008064. doi: 10.1371/journal.pcbi.1008064. eCollection 2020 Aug.
10
Human Natural Antibodies to Mammalian Carbohydrate Antigens as Unsung Heroes Protecting against Past, Present, and Future Viral Infections.人类对哺乳动物碳水化合物抗原的天然抗体是抵御过去、现在和未来病毒感染的无名英雄。
Antibodies (Basel). 2020 Jun 22;9(2):25. doi: 10.3390/antib9020025.

本文引用的文献

1
Flow microfluorometric analysis of peripheral blood mononuclear cells from nonhuman primates: Correlation of phenotype with immune function.非人灵长类动物外周血单个核细胞的流式微量荧光分析:表型与免疫功能的相关性
Am J Primatol. 1989;17(2):107-131. doi: 10.1002/ajp.1350170202.
2
Phagocytic processing of antigens for presentation by MHC molecules.抗原的吞噬处理,以便由MHC分子呈递。
Trends Cell Biol. 1995 Mar;5(3):105-9. doi: 10.1016/s0962-8924(00)88959-x.
3
Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo.抗原-抗体免疫复合物使树突状细胞能够在体内有效启动特异性CD8+细胞毒性T淋巴细胞反应。
J Immunol. 2002 Mar 1;168(5):2240-6. doi: 10.4049/jimmunol.168.5.2240.
4
Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques.在急性猿猴免疫缺陷病毒(SIV)感染期间给予重组恒河猴白细胞介素-12,可使感染SIVmac251的恒河猴的病毒载量降低,并延长其生存期。
J Virol. 2002 Feb;76(4):1731-43. doi: 10.1128/jvi.76.4.1731-1743.2002.
5
Enhanced in vitro stimulation of rhesus macaque dendritic cells for activation of SIV-specific T cell responses.增强恒河猴树突状细胞的体外刺激以激活SIV特异性T细胞反应。
J Immunol Methods. 2002 Feb 1;260(1-2):219-34. doi: 10.1016/s0022-1759(01)00544-0.
6
Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status.将未感染猿猴免疫缺陷病毒(SIV)的自体CD4(+)细胞过继转移至长期感染SIV的猕猴体内足以诱导长期非进展状态。
Blood. 2002 Jan 15;99(2):590-9. doi: 10.1182/blood.v99.2.590.
7
Optimized insect cell culture for the production of recombinant heterologous proteins and baculovirus particles.
Biotechniques. 2001 Dec;31(6):1262, 1264, 1266, 1268. doi: 10.2144/01316bm07.
8
A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.可变区3(V3)突变决定了一种与广泛交叉反应的原发性病毒中和抗体反应相关的人类免疫缺陷病毒1型包膜的整体中和表型和不依赖CD4的感染性。
J Virol. 2002 Jan;76(2):644-55. doi: 10.1128/jvi.76.2.644-655.2002.
9
Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes.用PSA/抗PSA(抗原/抗体)复合物武装的树突状细胞产生CD4(+)和CD8(+) T淋巴细胞反应。
Clin Immunol. 2001 Dec;101(3):276-83. doi: 10.1006/clim.2001.5115.
10
Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.一组针对1型人类免疫缺陷病毒的广泛中和抗体突变体的效应器功能活性。
J Virol. 2001 Dec;75(24):12161-8. doi: 10.1128/JVI.75.24.12161-12168.2001.

抗体介导增强猿猴免疫缺陷病毒(SIV)感染的恒河猴体内SIV Gag抗原加工及交叉呈递的证据。

Evidence for antibody-mediated enhancement of simian immunodeficiency virus (SIV) Gag antigen processing and cross presentation in SIV-infected rhesus macaques.

作者信息

Villinger Francois, Mayne Ann E, Bostik Pavel, Mori Kazuyasu, Jensen Peter E, Ahmed Rafi, Ansari Aftab A

机构信息

Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.

出版信息

J Virol. 2003 Jan;77(1):10-24. doi: 10.1128/jvi.77.1.10-24.2003.

DOI:10.1128/jvi.77.1.10-24.2003
PMID:12477806
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC140624/
Abstract

By using the dominant simian immunodeficiency virus (SIV) Gag Mamu-A01 restricted major histocompatibility complex (MHC) class I epitope p11CM, we demonstrate antibody-mediated enhanced MHC class I cross presentation of SIV Gag. In vitro restimulation of peripheral blood mononuclear cells from SIV-infected rhesus macaques with recombinant full-length SIV Gag p55 plus p55 affinity-purified immunoglobulin G (p55 Gag/p55-IgG) led to the generation of markedly higher frequencies of p11CM specific precursor cytotoxic T lymphocytes (p-CTLs) compared with restimulation with (i) SIV Gag p55 alone or (ii) optimal concentrations of the p11CM peptide alone. These results, along with the finding that CD4 depletion abrogated the enhancement, suggest a prominent role for CD4(+) T cells. Testing for p-CTLs against other Mamu-A01-restricted SIV Gag epitopes suggested that this mechanism favored recognition of the dominant p11CM peptide, potentially further skewing of the CTL response. The p-CTL enhancing effect was also decreased or abrogated by pepsin digestion of the p55-specific IgG or by the addition of monoclonal antibodies to Fc receptor (FcR) II/III, suggesting that the effect was dependent on FcR-mediated uptake of the immune-complexed antigen. Finally, incubation of antigen-presenting cells with SIV Gag p55 immune complexes in the presence of lactacystin or of bafilomycin indicated that the mechanism of antibody-mediated enhancement of cross presentation required both the proteasomal and the endosomal pathways. These data demonstrate for the first time the cross presentation of antigens via immune complexes in lentiviral infection and indicate a heretofore-unrecognized role for antibodies in modulating the magnitude and potentially also the breadth of MHC class I-restricted antigen processing and presentation and CTL responses.

摘要

通过使用主要的猿猴免疫缺陷病毒(SIV)Gag Mamu - A01限制性主要组织相容性复合体(MHC)I类表位p11CM,我们证明了抗体介导的SIV Gag的MHC I类交叉提呈增强。用重组全长SIV Gag p55加p55亲和纯化的免疫球蛋白G(p55 Gag/p55 - IgG)对SIV感染的恒河猴外周血单核细胞进行体外再刺激,与用(i)单独的SIV Gag p55或(ii)单独的最佳浓度的p11CM肽进行再刺激相比,导致产生的p11CM特异性前体细胞毒性T淋巴细胞(p - CTL)频率显著更高。这些结果,连同CD4耗竭消除增强作用这一发现,表明CD4(+) T细胞起重要作用。针对其他Mamu - A01限制性SIV Gag表位的p - CTL检测表明,该机制有利于识别主要的p11CM肽,可能进一步使CTL反应发生偏差。p55特异性IgG经胃蛋白酶消化或添加针对Fc受体(FcR)II/III的单克隆抗体也会降低或消除p - CTL增强作用,这表明该作用依赖于FcR介导的免疫复合物抗原摄取。最后,在存在乳胞素或巴弗洛霉素的情况下,用SIV Gag p55免疫复合物孵育抗原呈递细胞表明,抗体介导的交叉提呈增强机制需要蛋白酶体和内体途径。这些数据首次证明了慢病毒感染中通过免疫复合物进行抗原交叉提呈,并表明抗体在调节MHC I类限制性抗原加工、提呈的幅度以及潜在的广度和CTL反应方面具有迄今未被认识的作用。